Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma

Liver International

Volumn 30, Issue 1, 2010, Pages 139-148

  Ko, Frankie Chi Fat ^a   Yeung, Yin Shan ^a   Wong, Chun Ming ^a   Chan, Lo Kong ^a   Poon, Ronnie Tung Ping ^a   Ng, Irene Oi Lin ^a   Yam, Judy Wai Ping ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Deleted in liver cancer 1; Hepatocellular carcinoma; Isoforms

Indexed keywords

DELETED IN LIVER CANCER 1 ALPHA; DELETED IN LIVER CANCER 1 BETA; DELETED IN LIVER CANCER 1 GAMMA; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN ISOFORMS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 73349090904     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02133.x     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Lee JM, Wong CM, Ng I.O. Hepatitis B virus-associated multistep hepatocarcinogenesis: a stepwise increase in allelic alterations. Cancer Res 2008; 68: 5988-96.
3. Wong CM, Ng I.O. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008; 28: 160-74.
4. Yuan BZ, Miller MJ, Keck CL, et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998; 58: 2196-9.
5. Ng IO, Liang ZD, Cao L, Lee T.K. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res 2000; 60: 6581-4.
6. Kim TY, Lee JW, Kim HP, et al. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun 2007; 355: 72-7.
7. Wong CM, Yam JW, Ching YP, et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005; 65: 8861-8.
8. Zhou X, Zimonjic DB, Park SW, et al. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol 2008; 32: 1285-91.
9. Zhou X, Thorgeirsson SS, Popescu N.C. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 2004; 23: 1308-13.
10. Xue W, Krasnitz A, Lucito R, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 2008; 22: 1439-44.
11. Song YF, Xu R, Zhang XH, et al. High frequent promoter hypermethylation of DLC-1 gene in multiple myeloma. J Clin Pathol 2006; 59: 947-51.
12. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu N.C. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res 2006; 12: 1412-9.
13. Yuan BZ, Durkin ME, Popescu N.C. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 2003; 140: 113-7.
14. Kim TY, Jong HS, Song SH, et al. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 2003; 22: 3943-51.
15. Seng TJ, Low JS, Li H, et al. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 2007; 26: 934-44.
16. Wong CM, Lee JM, Ching YP, Jin DY, Ng I.O. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003; 63: 7646-51.
17. Zhang Q, Ying J, Zhang K, et al. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett 2007; 249: 220-6.
18. Ching YP,Wong CM, Chan SF, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003; 278: 10824-30.
19. Kawai K, Kiyota M, Seike J, Deki Y, Yagisawa H. STARTGAP3/ DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem Biophys Res Commun 2007; 364: 783-9.
20. Yam JW, Ko FC, Chan CY, Jin DY, Ng I.O. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res 2006; 66: 8367-72.
21. Qian X, Li G, Asmussen HK, et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA 2007; 104: 9012-7.
22. Liao YC, Si L, deVere White RW, Lo S.H. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol 2007; 176: 43-9.
23. Nagase T, Kikuno R, Hattori A, et al. Prediction of the coding sequences of unidentified human genes. X.I.X. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 2000; 7: 347-55.
24. Durkin ME, Yuan BZ, Zhou X, et al. DLC-1: a Rho GTPaseactivating protein and tumour suppressor. J Cell Mol Med 2007; 11: 1185-207.
25. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles B.B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979; 282: 615-6.
26. Cheng RM, Zhu DH, Ye XZ, Shen B.W. Establishment and some biological characteristics of human hepatocellular cell line Bel7402. Acta Biol Exp Sin 1978; 11: 37-45.
27. Tong R, Zhou R, Lu F, Tao W. The establishment and primary biological characteristics of human hepatoma SMMC-7721 cell line. J 2nd Milit Med Univ 1980; 1: 5-9.
28. Liao YC, Shih YP, Lo S.H. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res 2008; 68: 7718-22.
29. Chan LK, Ko FC, Ng IO, Yam J.W. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One 2009; 4: e5572.
30. Kobayashi N, Takeshima H, Fukushima H, et al. Cardioprotective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts. Am J Hypertens 2009; 22: 176-82.
31. Kim TY, Healy KD, Der CJ, et al. Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. J Biol Chem 2008; 283: 32762-70.
32. Feitelson MA, Sun B, Satiroglu Tufan NL, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21: 2593-604.
33. Durkin ME, Avner MR, Huh CG, et al. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 2005; 579: 1191-6.
34. Wong CC, Wong CM, Ko FC, et al. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS ONE 2008; 3: e2779.